EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – Poster
Antitumor activity of STRO-002, a novel anti-folate receptor -⍺ (FolR⍺) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Please Click the Link, AACR...
Sutro Biopharma to Present at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer - Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer...
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2019 – STRO-002 – Abstract
Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary Phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC) Denise Uyar, 1 Russell J...
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held Oct. 26-30, 2019, in Boston....
World Anti-Body Drug Conjugate (ADC) 2019 – Process Development and Scale Up for Site-Specific Bioconjugate Conjugation and Purification Poster
Please Click the Link, World ADC 2019 Poster to enlarge.
Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 4, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40...
Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Aug. 8, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., June 18, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
SOUTH SAN FRANCISCO, Calif., May 16, 2019 – Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that the company will present at the upcoming European Hematology Association (EHA) Congress being held June 13-16, 2019, in Amsterdam. The abstract summarizes preliminary...
Sutro Biopharma to Present at the Cowen and Company 39th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 5, 2019 –Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11 at 2:50 p.m. ET at the Marriott...
